UK backs CureVac effort to make vaccine for COVID variants

The UK government says it will support a German biopharmaceutical company’s effort to develop vaccines to combat new variants of COVID-19, once again supporting early-stage research into products meant to control the pandemic

Earlier this week, drugmaker GlaxoSmithKline said it would invest in CureVac for the development of new vaccines targeting emerging variants, using its messenger RNA technology to attack the disease. GSK said it plans to invest 150 million euros ($181 million) in the project.

CureVac said its collaboration with the U.K. will support both the vaccines it is developing with GSK as well as another vaccine candidate it is developing with Bayer that is already in human trials.


Follow all of AP’s pandemic coverage at, and

Be the first to comment

Leave a Reply

Your email address will not be published.